The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.
The company estimated that the offering could raise between $327.2 and $376.3 million, which it would use for various corporate purposes.
The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.
The decrease came as improved performance by its biopharma services operations was more than offset by declines in clinical and discovery services revenues.
The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.
The firms anticipate discovering and validating a biomarker signature, or signatures, for earlier detection of pulmonary hypertension and its subtypes.
Oxford Immunotec said that it expects the report to further the trend toward interferon-gamma release assay adoption for healthcare personnel screening.
A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.
After conducting a head-to-head comparison with competing instruments, clinicians selected the Abbott iStat instrument to monitor blood clotting during surgical interventions.
A decades-long decline in medical technician training programs and large numbers of looming retirements have labs scrambling to fill their vacancies.